The Genetics Podcast

0:00 Intro

0:25 Mazen’s lifelong commitment to furthering the field of precision medicine in liver disease research, fueled by a personal connection of his grandmother developing MASH cirrhosis

2:30 Breakthroughs in the field of metabolic dysfunction-associated steatotic liver disease (MASLD) since the beginning of Mazen’s career

5:30 The potential impact of Resmetirom, a new drug that could treat MASLD and MASH cirrhosis

8:45 Significant takeaways from 40+ investigational clinical studies of novel treatments for MASLD/MASH 

12:00 Alternatives to biopsies and potential tools for early, non-invasive diagnosis

19:00 Genetic determinants and risk factors for fatty liver diseases

20:30 How Mazen uses genetic testing in the clinic for his patients

25:50 The impact of “miracle” weight loss drugs such as GLP-1s on patients with liver disease

29:30 The importance of early intervention to prevent late-stage cirrhosis 

33:00 How to tailor treatment to consider environmental and epigenetic factors that impact genetic penetrance for liver disease

36:00 Potential links between metabolism and neurodegenerative conditions

39:00 Upcoming developments in MASLD and MASH research

41:00 Mazen’s  relationship with his father, both as a dad and as a teacher